New Genetic Sequencing May Lead to Urine Test for Bladder Cancer

Share this content:
Early research indicates the possibility for a urine test for bladder cancer.
Early research indicates the possibility for a urine test for bladder cancer.

Oncologists in the not too distant future may have a urine test to screen for bladder cancer.

Colorado investigators reported at the American Association for Cancer Research (AACR) Annual Meeting 2015 that specific gene alterations happen early in the development of bladder cancer and so it may be possible to develop a genetic test that examines urine as a way to screen for the disease.

The researchers examined bladder cancer tumors from 54 patients and found that telomerase (TERT) is the gene most frequently altered by somatic sequence changes.

This was found to occur in 37 out of the 54 tumors (69%). TERT was also altered by rare and common germline variants in 30 out of the 54 tumors (56%).

The researchers reported that TERT germline variants were novel in 19 out of 20 tumors and three variants were confirmed as both somatic and germline in distinct tumors.

“We are moving into a new era,” said senior study author Dan Theodorescu, MD, PhD, who is the director of the Colorado University Cancer Center in Denver, CO. Gene sequencing for bladder cancer is expanding rapidly and Dr. Theodorescu and his colleagues found that TERT alterations frequently co-occur with alterations in recently identified bladder cancer genes such as the stromal antigen 2 (STAG2) and the lysine-specific demethylase 6A (KDM6A).

The researchers found that somatic alterations occurred in 15% of tumors in the BRCA1-associated protein-1 (BAP1) gene, a gene recently characterized in the development of bladder cancer.

The BAP1 alterations co-occurred with KDM6A mutations and contributed to a high frequency of BRCA pathway defects due to germline and somatic alteration of BRCA1, BRCA2, ATM, and PALB2.

RELATED: Neoadjuvant GC with MVAC Have Comparable Efficacy in Bladder Cancer

Prior studies have shown that BRCA1- and BRCA2-mutant breast, ovarian, and prostate cancers are responsive to the class of drugs known as poly (ADP-ribose) polymerase (PARP) inhibitors.

Study co-author Michael Nickerson, PhD, who is a staff scientist the National Cancer Institute (NCI) in Bethesda, MD, said it is hoped that U.S. Food and Drug Administration (FDA)-approved drugs such as PARP inhibitors that are currently being developed to treat BRCA-mutant cancers may be effective in treating the potentially large number of patients with bladder cancer with BRCA DNA repair pathway defects.

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters